小児原発中枢神経系腫瘍患者のトズレリスチドの第1期および拡張画像検査
Amy Lee1,2, Bonnie L Cole3,4, Jeffrey Ojemann1,2
11Division of Pediatric Neurosurgery, Seattle Children's Hospital.
Journal of neurosurgery. Pediatrics
|August 29, 2025
まとめ
トズレリスチドは小児の脳腫瘍に対する 安全な光剤です 手術中に腫瘍の組織を効果的に強調し 腫瘍と健康な組織を区別するのに 手術師を助けます
科学分野:
- 腫瘍学
- 神経外科
- 薬理学について
背景:
- 光による手術は,成人の腫瘍切除の範囲を高めます.
- トズレリスチドは,中枢神経系腫瘍の可視化のための試験用ペプチド染料コンジュガートです.
研究 の 目的:
- 小児の中枢神経腫瘍におけるトズレリスチドの安全性,薬動性,および光性を評価する.
- トズレリスチドのフェーズ2試験の最適な用量を決定する.
主な方法:
- 小児患者におけるトズレリスチドの投与量エスカレーション試験 (1. 7~17. 3 mg/ m2).
- 安全性,薬動性,画像データ収集; 15 mg/ m2の投与量拡大
主要な成果:
- トズレリスチドは投与量を制限する毒性や有害事象は認められませんでした.
- 高用量 (13. 917. 3 mg/ m2) では,腫瘍の光が有意に増加した.
- 切除された組織では81%の感度と93%のPPVが観察されました.
結論:
- トズレリスチドは安全で,中枢神経系の腫瘍を患う小児患者でよく耐える.
- トズレリスチドによる光画像は,様々な小児の中枢神経腫瘍の潜在性を示しています.
- トズレリスチドは神経外科医に腫瘍と正常な組織を区別するのに役立ちます.
さらに関連する動画
05:22Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
3.3K
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.5K
関連する概念動画
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drug Administration and Therapy Phases: Overview
738
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
738
